• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用亲脂性和碱性进行药物发现时对人醚-去极化相关基因钾通道抑制的风险评估。

A risk assessment of human ether-a-go-go-related gene potassium channel inhibition by using lipophilicity and basicity for drug discovery.

作者信息

Kawai Yukinori, Tsukamoto Shinsaku, Ito Junko, Akimoto Katsuya, Takahashi Masayuki

机构信息

Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Japan..

出版信息

Chem Pharm Bull (Tokyo). 2011;59(9):1110-6. doi: 10.1248/cpb.59.1110.

DOI:10.1248/cpb.59.1110
PMID:21881254
Abstract

The blockade of human ether-a-go-go-related gene (hERG) potassium channels is widely regarded as the predominant cause of drug-induced QT prolongation. The correlation analysis between the inhibition of the hERG channel (hERG inhibition) and physicochemical properties was investigated by use of in-house quinolone antibiotics as model compounds. In order to establish a simple prediction model of hERG inhibition, we focused on the comprehensible physicochemical parameters such as lipophilicity (log P) and basicity (pK(a)). At first, the risk associated with increasing log P and pK(a) was examined by statistical analysis. It was demonstrated that the risk associated with increasing log P and pK(a) by one unit, respectively, almost identically increased. Consequently, equal attention should be paid to both parameters on hERG inhibition. Next, a prediction model of hERG inhibition which was represented by log P and pK(a) was investigated. As a result, we built the stepwise discriminant prediction model which took advantage of the risk judgment by zone classification. In conclusion, the impact of log P and pK(a) on hERG inhibition was clarified relatively and quantitatively. The quantitative risk assessment established based on both parameters, was considered to be a practical and useful tool in avoiding hERG inhibition and in the rational drug design for drug discovery, especially in lead optimization. Moreover, we also carried out a trend analysis using a different derivative and demonstrated that both parameters were equally significant for hERG inhibition.

摘要

人类醚 - 去极化相关基因(hERG)钾通道的阻断被广泛认为是药物诱导的QT间期延长的主要原因。以内部喹诺酮类抗生素为模型化合物,研究了hERG通道抑制(hERG抑制)与理化性质之间的相关性分析。为了建立一个简单的hERG抑制预测模型,我们关注了诸如亲脂性(log P)和碱性(pK(a))等易于理解的理化参数。首先,通过统计分析研究了log P和pK(a)增加所带来的风险。结果表明,log P和pK(a)分别增加一个单位所带来的风险几乎相同程度地增加。因此,在hERG抑制方面应同等重视这两个参数。接下来,研究了以log P和pK(a)表示的hERG抑制预测模型。结果,我们构建了逐步判别预测模型,该模型利用区域分类进行风险判断。总之,相对定量地阐明了log P和pK(a)对hERG抑制的影响。基于这两个参数建立的定量风险评估,被认为是避免hERG抑制以及在药物发现尤其是先导化合物优化中的合理药物设计中的实用且有用的工具。此外,我们还使用不同的衍生物进行了趋势分析,并证明这两个参数对hERG抑制同样重要。

相似文献

1
A risk assessment of human ether-a-go-go-related gene potassium channel inhibition by using lipophilicity and basicity for drug discovery.利用亲脂性和碱性进行药物发现时对人醚-去极化相关基因钾通道抑制的风险评估。
Chem Pharm Bull (Tokyo). 2011;59(9):1110-6. doi: 10.1248/cpb.59.1110.
2
BeKm-1, a peptide inhibitor of human ether-a-go-go-related gene potassium currents, prolongs QTc intervals in isolated rabbit heart.BeKm-1,一种人 ether-a-go-go 相关基因钾电流的肽类抑制剂,可延长离体兔心的 QTc 间期。
J Pharmacol Exp Ther. 2011 Apr;337(1):2-8. doi: 10.1124/jpet.110.176883. Epub 2010 Dec 23.
3
Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model.使用hERG抑制和麻醉豚鼠模型预测人类在药物早期开发过程中的QT间期延长。
Br J Pharmacol. 2008 Aug;154(7):1446-56. doi: 10.1038/bjp.2008.267. Epub 2008 Jun 30.
4
A history of the role of the hERG channel in cardiac risk assessment.hERG通道在心脏风险评估中作用的历史。
J Pharmacol Toxicol Methods. 2013 Jul-Aug;68(1):13-22. doi: 10.1016/j.vascn.2013.03.005. Epub 2013 Mar 26.
5
Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade.化合物QT延长效应的早期评估:一种用于测量hERG阻断的预测性384孔荧光偏振结合测定法。
J Pharmacol Toxicol Methods. 2007 May-Jun;55(3):238-47. doi: 10.1016/j.vascn.2006.09.003. Epub 2006 Oct 18.
6
[Lead compound optimization strategy(5) – reducing the hERG cardiac toxicity in drug development].
Yao Xue Xue Bao. 2016 Oct;51(10):1530-9.
7
Acquired QT interval prolongation and HERG: implications for drug discovery and development.获得性QT间期延长与人类ether-a-go-go相关基因(HERG):对药物研发的影响
Eur J Pharmacol. 2004 Oct 1;500(1-3):129-42. doi: 10.1016/j.ejphar.2004.07.019.
8
Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.整理、评估和分析关于hERG受体阻断效力的体外文献数据,以便后续对药物的心脏毒性特性进行建模。
J Appl Toxicol. 2009 Apr;29(3):183-206. doi: 10.1002/jat.1395.
9
Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics.大环内酯类抗生素对人类心脏钾通道——人类醚-去极化相关基因(HERG)的阻断作用。
J Pharmacol Exp Ther. 2002 Jul;302(1):320-7. doi: 10.1124/jpet.302.1.320.
10
Overcoming hERG affinity in the discovery of maraviroc; a CCR5 antagonist for the treatment of HIV.
Curr Top Med Chem. 2008;8(13):1140-51. doi: 10.2174/156802608785700007.

引用本文的文献

1
Effect of the Membrane Environment on Pharmacologic Inhibition of hERG K Channel Activity.膜环境对人乙醚-a- go-go相关基因(hERG)钾通道活性的药理学抑制作用
JACC Clin Electrophysiol. 2025 Apr;11(4):708-719. doi: 10.1016/j.jacep.2024.11.016. Epub 2025 Jan 29.
2
Metabolic and electrolyte abnormalities as risk factors in drug-induced long QT syndrome.代谢和电解质异常作为药物性长QT综合征的危险因素。
Biophys Rev. 2022 Jan 27;14(1):353-367. doi: 10.1007/s12551-022-00929-7. eCollection 2022 Feb.
3
Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity.
氟环丙基酰胺的立体化学差异可实现布鲁顿酪氨酸激酶(Btk)抑制作用和脱靶活性的调控。
ACS Med Chem Lett. 2020 Jul 13;11(8):1588-1597. doi: 10.1021/acsmedchemlett.0c00249. eCollection 2020 Aug 13.
4
Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar Moiety.选择性PAK1抑制剂G-5555的设计:通过采用非传统的低pKₐ极性部分改善性能。
ACS Med Chem Lett. 2015 Oct 31;6(12):1241-6. doi: 10.1021/acsmedchemlett.5b00398. eCollection 2015 Dec 10.